SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Renewed Middle East tensions and fears of oil-supply disruptions have driven crude higher and lifted USO. Traders are divided between expecting the rally to continue and warning that the move is overextended and could reverse if tensions ease.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps rally and heavy bullish call activity are drawing attention ahead of its upcoming earnings report, with traders also focused on the Specs AR-glasses business, including Robert Downey Jr.s promotional campaign and an activist proposal to sell a stake in the unit. Bulls see improving ad monetization and cost controls as signs of a turnaround, while skeptics warn the move may be driven by options speculation and remains vulnerable to earnings and advertising uncertainty.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

PHAT is under pressure after generic-drug maker BDR sued the FDA over VOQUEZNAs exclusivity, raising concern that generic competition could arrive earlier than expected. Traders are divided between viewing the case as a meaningful legal overhang and dismissing it as unlikely to overturn the FDAs decision; many emphasize that the dispute is not a drug failure or confirmation that a generic has been approved.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is falling despite an earnings beat and higher full-year profit guidance, with traders focusing on plans to cut about 5% of its workforce and rising expenses; revenue also narrowly missed expectations. The reaction is debated, as some view the results and outlook as strong while others see the restructuring and cost pressures as reasons for caution.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on CRISPR Therapeutics upcoming CTX310 Phase 1b data presentation at the AHA, which traders view as a key test of its in-vivo gene-editing program. The CFOs departure has added concern, though some traders note it was described as an orderly internal handoff with no reported disagreement.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSkys expanded seven-figure Gen-3 contract with an unnamed international defense partner is drawing attention, though traders note the positive contract news has not translated into a stronger share price. The discussion is split between confidence in contract growth and concern over BKSYs decline, weakness across space stocks, and the upcoming earnings report.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroups quarterly earnings beat estimates, but the shares sold off, prompting debate over why strong results have not lifted the stock. Bulls view the pullback as a buying opportunity and point to support levels, while bearish traders focus on continued selling and credit concerns.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons breakout to record highs is drawing attention as crude prices rise amid Middle East supply concerns, with traders also positioning ahead of earnings. The mood is largely bullish on the momentum, though some are cautious about whether the oil-driven rally can hold through the report.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

Healthcare-sector strength and rotation toward defensive stocks are driving XLV discussion, with traders pointing to a rebound from technical support and a push to fresh highs as the sector outperformed tech. Some see the advance continuing, while others caution that the rally is volatile and may need a pullback or further confirmation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is drawing attention after a steep selloff to fresh 52-week lows, with traders pointing to the recent financing, broader biotech weakness and declining confidence in management. The debate is between bulls focused on VK2735s obesity-trial potential and possible partnership or buyout interest, and bears concerned about dilution and the long wait for Phase 3 data; investors are watching the Q3 earnings call for strategic or pipeline updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies and services in the cell and gene therapy industry. It operates through the following segments: Octomera and Therapies. The Octomera segment refers to the point-of-care services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Orgenesis Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.40
Prev Close	$0.044
Open	$0.0467
Dividend Yield	N/A
50-Day Moving Average	$0.3253
Beta	636.62
Avg. Volume	729.90
PE Ratio	N/A

52-Week High	$0.91
52-Week Low	$0.0001
Market Capitalization	$3.92M
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

ORGS Fundamentals